Vestibular Migraine: The Dizziness-Migraine Connection Most Doctors Miss

Why Vestibular Migraine Is So Underdiagnosed

Vestibular migraine (VM) is the most common neurological cause of recurrent spontaneous vertigo, affecting an estimated 1-2.7% of the general population [1]. Despite this prevalence, it remains underdiagnosed for two reasons: many attacks occur without headache, and dizziness sends patients to ENTs or primary care rather than neurologists or headache specialists.

The result is years of misdiagnosis. Patients get labeled with Meniere’s disease, benign paroxysmal positional vertigo (BPPV), anxiety-related dizziness, or “inner ear problems.” A 2012 retrospective study found that the average time from symptom onset to correct diagnosis was 5.4 years [2].

What Vestibular Migraine Feels Like

VM attacks involve vestibular symptoms that are moderate to severe and last between 5 minutes and 72 hours. The vestibular symptoms are diverse and can include:

• Spontaneous vertigo: A spinning sensation as if the room is moving around you, or you are spinning while the room stays still
• Positional vertigo: Vertigo triggered by head position changes (can mimic BPPV, but the nystagmus pattern is different)
• Head motion-induced dizziness: Disorientation, imbalance, or nausea triggered by head movements
• Visual vertigo: Dizziness triggered by complex or moving visual stimuli (grocery store aisles, scrolling on screens, busy traffic patterns)
• Persistent disequilibrium: A floating, rocking, or swaying sensation that lasts hours to days, even without true rotational vertigo

Accompanying symptoms during attacks may include nausea, photophobia, phonophobia, motion sensitivity, and spatial disorientation. Headache is present in about 70% of attacks but absent in 30%, which is why the vestibular component often overshadows the migraine diagnosis [3].

Diagnostic Criteria

The International Classification of Headache Disorders (ICHD-3) and the Barany Society jointly published diagnostic criteria in 2012, updated in 2018 [4]:

Definite Vestibular Migraine requires all of:

1. At least 5 episodes of vestibular symptoms of moderate or severe intensity, lasting 5 minutes to 72 hours
2. Current or previous history of migraine with or without aura (per ICHD criteria)
3. One or more migraine features with at least 50% of vestibular episodes: headache with migraine characteristics, photophobia and phonophobia, visual aura
4. Not better accounted for by another vestibular or ICHD diagnosis

Probable Vestibular Migraine: Meets criteria 1 and 2, plus either criterion 3 or 4 but not both.

What Causes It

The pathophysiology of vestibular migraine is not fully understood, but several mechanisms are implicated [5]:

• Trigeminal innervation of the inner ear: The trigeminal nerve innervates the cochlea and vestibular labyrinth. Trigeminovascular activation during migraine releases CGRP and other neuropeptides in the inner ear, altering vestibular function.
• Central vestibular processing dysfunction: The vestibular nuclei in the brainstem receive convergent input from trigeminal and vestibular pathways. During migraine, altered serotonergic and glutamatergic signaling in these nuclei produces vestibular symptoms.
• Cortical spreading depression: CSD extending into the vestibular cortex (posterior insula, temporoparietal junction) may directly produce vertigo during aura.
• Ion channel dysfunction: Shared genetic susceptibility between migraine and vestibular disorders, particularly calcium channel variants (CACNA1A mutations are linked to both familial hemiplegic migraine and episodic ataxia type 2).

How to Differentiate VM from Other Causes of Vertigo

VM and Meniere’s disease can coexist and overlap. Up to 45% of Meniere’s patients also meet criteria for VM. If hearing loss, tinnitus, or ear fullness are prominent, audiometry is essential [6].

Testing and Workup

There is no diagnostic test for vestibular migraine. Diagnosis is clinical, based on the criteria above. However, testing serves to rule out alternative diagnoses:

• Audiometry: Normal in VM (abnormal suggests Meniere’s or other otologic cause)
• Videonystagmography (VNG): May show central or mixed patterns during attacks. Between attacks, often normal.
• MRI brain: Recommended for first presentation to rule out posterior fossa lesion, vestibular schwannoma, or demyelinating disease
• VEMP (vestibular evoked myogenic potentials): May show subtle abnormalities in VM patients, supporting inner ear involvement

Normal testing between attacks is expected and does not rule out VM. The diagnosis rests on the clinical pattern.

Treatment

Acute Treatment

Acute VM attacks can be treated with [7]:

• Triptans: Effective for VM attacks that include headache. Zolmitriptan nasal spray is useful when nausea prevents oral intake.
• Vestibular suppressants: Meclizine (25 mg), dimenhydrinate (50 mg), or promethazine (25 mg) reduce vertigo and nausea during acute attacks. Use sparingly: chronic vestibular suppressant use delays central compensation and can worsen long-term outcomes.
• Benzodiazepines: Low-dose lorazepam (0.5 mg) or diazepam (2-5 mg) for severe acute vertigo. Short-term use only.

Preventive Treatment

Preventive therapy is recommended when VM attacks occur more than once per month or are significantly disabling. The same migraine preventives used for headache prevention are effective:

• Beta-blockers (propranolol, metoprolol): First-line in many headache centers. Propranolol 40-160 mg/day. Good evidence from retrospective studies showing 50-70% reduction in VM frequency.
• Venlafaxine: 37.5-150 mg/day. A retrospective cohort study showed 58% of VM patients achieved 50% or greater reduction in vertigo episodes [8].
• Topiramate: 50-100 mg/day. Effective but cognitive side effects may be limiting.
• Amitriptyline: 10-75 mg at bedtime. Particularly useful when insomnia or tension-type headache overlap is present.
• Anti-CGRP antibodies: Emerging evidence supports erenumab and galcanezumab for VM. A 2022 open-label study of erenumab showed significant reduction in both vertigo days and headache days in VM patients [9].
• Lamotrigine: Some evidence for VM with prominent aura. 25-100 mg/day.

Vestibular Rehabilitation

Vestibular rehabilitation therapy (VRT) is a specialized physical therapy program that trains the brain to compensate for vestibular dysfunction. For VM patients, VRT improves:

• Balance and gait stability
• Tolerance to head movement
• Visual motion tolerance
• Confidence with daily activities

VRT is most effective when combined with migraine preventive medication. A 2019 study found that VRT + medication outperformed medication alone for dizziness handicap scores in VM [10].

Lifestyle Modifications

VM responds to the same lifestyle optimizations as migraine generally:

• Sleep hygiene: Consistent sleep-wake schedule (within 30 minutes daily)
• Hydration: Minimum 2-3 liters daily; dehydration is a potent VM trigger
• Caffeine consistency: Stable, moderate intake (or none). Fluctuating caffeine intake triggers attacks.
• Stress management: Regular exercise, mindfulness, or yoga. The “let-down” period after stress is a common VM trigger window.
• Dietary triggers: MSG, aged cheese, red wine, and artificial sweeteners are reported triggers. Track individually rather than eliminating broadly.

The Overlap with PPPD (Persistent Postural-Perceptual Dizziness)

VM and PPPD frequently coexist. PPPD is characterized by persistent, non-spinning dizziness worsened by upright posture, active or passive motion, and complex visual stimuli. It develops as a maladaptive response to an initial vestibular insult, which in many cases is VM itself.

When VM triggers PPPD, treatment needs to address both: migraine preventives for the episodic VM component, and SSRI/SNRI therapy plus habituation-based VRT for the chronic PPPD component.

Related Reading

• Migraine: The Evidence-Based Guide (Pillar)
• Migraine with Aura: What It Looks Like and When to Worry
• Migraine Treatment: Medications, Preventives, and Regenerative Options

References

1. Neuhauser HK, Radtke A, von Brevern M, et al. Migrainous vertigo: prevalence and impact on quality of life. Neurology. 2006;67(6):1028-1033. doi:10.1212/01.wnl.0000237539.09942.06
2. Dieterich M, Obermann M, Celebisoy N. Vestibular migraine: the most frequent entity of episodic vertigo. J Neurol. 2016;263(Suppl 1):S82-S89. doi:10.1007/s00415-015-7905-2
3. Beh SC, Masrber S, Smith A, et al. The spectrum of vestibular migraine: clinical features, triggers, and examination findings. J Vestib Res. 2019;29(2-3):173-183. doi:10.3233/VES-190660
4. Lempert T, Olesen J, Furman J, et al. Vestibular migraine: diagnostic criteria. J Vestib Res. 2012;22(4):167-172. doi:10.3233/VES-2012-0453
5. Furman JM, Marcus DA, Balaban CD. Migrainous vertigo: development of a pathogenetic model and structured diagnostic interview. Curr Opin Neurol. 2003;16(1):5-13. doi:10.1097/00019052-200302000-00002
6. Radtke A, Lempert T, Gresty MA, et al. Migraine and Meniere’s disease: is there a link? Neurology. 2002;59(11):1700-1704. doi:10.1212/01.WNL.0000036903.22461.39
7. Maldonado Fernandez M, Birdi JS, Irving GJ, et al. Pharmacological agents for the prevention of vestibular migraine. Cochrane Database Syst Rev. 2015;(6):CD010600. doi:10.1002/14651858.CD010600.pub2
8. Salviz M, Yuce T, Acar H, et al. Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial. Laryngoscope. 2016;126(1):169-174. doi:10.1002/lary.25445
9. Hoskin JL, Fife TD. New anti-CGRP medications in the treatment of vestibular migraine. Front Neurol. 2022;13:945556. doi:10.3389/fneur.2022.945556
10. Sugaya N, Arai M, Goto F. Is the headache in patients with vestibular migraine attenuated by vestibular rehabilitation? Front Neurol. 2017;8:124. doi:10.3389/fneur.2017.00124